Skip to main content
. 2022 Apr 4;3(3):100239. doi: 10.1016/j.xinn.2022.100239

Figure 4.

Figure 4

Biomarker analysis

(A) Genetic landscape of 89 patients with sufficient pretreatment tumor material for targeted NGS.

(B and C) Kaplan-Meier curves of progression-free survival (B) and overall survival (C) for patients with EGFR amplification.

(D) Kaplan-Meier curves of progression-free survival in patients with 11q13 amplification.